𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A535 Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia

✍ Scribed by Ghobrial, IM; Roccaro, AM; Matous, J; Padmanabhan, W; Badros, A; Schlossman, R; Chuma, S; Leduc, R; Nelson, M; O'Connor, K; Sam, A; Harris, B; Soumerai, J; Warren, D; Birner, A; Munshi, NC; Treon, SP; Anderson, KC; Richardson, PG

Book ID
118629389
Publisher
CIG Media Group, LP.
Year
2009
Tongue
English
Weight
112 KB
Volume
9
Category
Article
ISSN
1557-9190

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of weekly bortezomib in c
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
✍ Irene M. Ghobrial; Wanling Xie; Swaminathan Padmanabhan; Ashraf Badros; Meghan R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB 👁 1 views

## Abstract This study aimed to determine the activity and safety of weekly bortezomib and rituximab in patients with untreated Waldenström Macroglobulinemia (WM). Patients with no prior therapy and symptomatic disease were eligible. Patients received bortezomib IV weekly at 1.6 mg/m^2^ on days 1,